Abstract
The treatment of bone-metastatic cancer now takes advantage of the unique biology of this clinical state. The complex interplay between the cancer cells and the bone microenvironment leads to a host of therapeutic targets, with agents in various stages of clinical use or study. Targets include interactions between the cancer cells and osteoclasts, osteoblasts, endothelial cells, stromal cells, hematopoietic progenitor cells, cells of the immune system, and the bone matrix. Efforts at understanding specific mechanisms of drug resistance in the bone are also ongoing. Successful clinical outcomes will be the result of co-targeting and interrupting the various tumor-supportive elements and cooperating pathways at the level of the tumor cell, the primary and metastatic microenvironments, and systemic cancer effects, leading to a "scaled network disruption" to undermine the disease state.
Original language | English (US) |
---|---|
Pages (from-to) | 545-553 |
Number of pages | 9 |
Journal | Cancer and Metastasis Reviews |
Volume | 33 |
Issue number | 2-3 |
DOIs | |
State | Published - Sep 2014 |
Keywords
- Bone metastasis
- Ecotherapy
- Microenvironment
- Prostate cancer
- Targeted therapy
ASJC Scopus subject areas
- Oncology
- Cancer Research